Pathogenesis of parvovirus B19 infection: Host gene variability, and possible means and effects of virus persistence

Journal of Veterinary Medicine Series B: Infectious Diseases and Veterinary Public Health

Volumn 52, Issue 7-8, 2005, Pages 335-339

  Kerr, J R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS;

GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; PARVOVIRUS; PATHOGENICITY; REVIEW; VIRUS INFECTION;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

EID: 33644687167     PISSN: 09311793     EISSN: 14390450     Source Type: Journal    
DOI: 10.1111/j.1439-0450.2005.00859.x     Document Type: Conference Paper

References (45)

1. Anderson, M. J., P. G. Higgins, L. R. Davis, J. S. Willman, S. E. Jones, I. M. Kidd, J. R. Pattison, and D. A. Tyrrell, 1985: Experimental parvoviral infection in humans. J. Infect. Dis. 152, 257-265.
2. Barah, F., P. J. Vallely, M. L. Chiswick, G. M. Cleator, J. R. Kerr, 2001: Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet 358, 729-730.
3. Berns, K. I. 1984: The Parvoviruses. Plenum Press, New York.
4. Cioc, A. M., D. D. Sedmak, G. J. Nuovo, M. R. Dawood, G. Smart, and C. M. Magro, 2002: Parvovirus B19 associated adult Henoch Schonlein purpura. J. Cutan. Pathol. 29, 602-607.
5. Corsini, J., J. Tal, and W. Winocaur, 1997: Directed integration of minute virus of mice DNA into episomes. J. Virol. 71, 9008-9015.
6. De Cat, B., and G. David, 2001: Developmental roles of the glypicans. Semin. Cell Dev. Biol. 12, 117-125.
7. Diss, T. C., L. X. Pan, M. Q. Du, H. Z. Peng, and J. R. Kerr, 1999: Parvovirus B19 is associated with benign testes as well as testicular germ cell tumours. Mol. Pathol. 52, 349-352.
8. Dorsch, S., G. Liebisch, B. Kaufmann, P. Von Landenberg, J. H. Hoffmann, W. Drobnik, and S. Modrow, 2002: The VP1-unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J. Virol. 76, 2014-2018.
9. Dunning, A. M., P. D. Ellis, S. McBride, H. L. Kirschenlohr, C. S. Healey, P. R. Kemp, R. N. Luben, J. Chang-Claude, A. Mannermaa, V. Kataja, P. D. Pharoah, D. F. Easton, B. A. Ponder, and J. C. Metcalfe, 2003: Transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 63, 2610-2615.
10. Foto, F., K. G. Saag, L. L. Scharosch, E. J. Howard, and S. J. Naides, 1993: Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. J. Infect. Dis. 167, 744-748.
11. Gendi, N. S., K. Gibson, and B. P. Wordsworth, 1996: Effect of HLA type and hypocomplementaemia on the expression of parvovirus arthritis: one year follow up of an outbreak. Ann. Rheum. Dis. 55, 63-65.
12. Jawad, A. S. 1993: Persistent parvovirus after human parvovirus B19 infection. Lancet 341, 494.
13. Kerr, J. R. 2005: Short regions of sequence homology between the genomes of human and rodent parvoviruses and their respective hosts occur within of genes of the cytoskeleton, cell adhesion and Wnt/notch signalling pathways. Poster at International Parvovirus Meeting, Leipzig, Germany.
14. Kerr, J. R., and S. Modrow, 2005: Human and Primate Erythrovirus Infections and Associated Disease. In: Kerr, J. R., S. F. Cotmore, M. E. Bloom, R. M. Linden, and C. R. Parrish (eds), Parvoviruses, pp. 385-416. Hodder Arnold, London.
15. Kerr, J. R., J. P. Cartron, M. D. Curran, J. E. Moore, J. R. Elliott, and R. A. Mollan, 1995: A study of the role of parvovirus B19 in rheumatoid arthritis. Br. J. Rheumatol. 34, 809-813.
16. Kerr, J. R., D. Kane, B. Crowley, N. Leonard, S. O'Briain, P. V. Coyle, and F. Mulcahy, 1997: Parvovirus B19 infection in AIDS patients. Int. J. STD AIDS 8, 184-186.
17. Kerr, J. R., F. Barah, D. L. Mattey, I. Laing, S. J. Hopkins, I. V. Hutchinson, and D. A. Tyrrell, 2001: Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J. Gen. Virol. 82, 3011-3019.
18. Kerr, J. R., J. Bracewell, I. Laing, D. L. Mattey, R. M. Bernstein, I. N. Bruce, and D. A. Tyrrell, 2002a: Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. J. Rheumatol. 29, 595-602.
19. Kerr, J. R., D. L. Mattey, W. Thomson,K. V. Poulton, and W. E. Ollier, 2002b: Association of symptomatic acute human parvovirus B19 infection with HLA class I and II alleles. J. Infect. Dis. 186, 447-452.
20. Kerr, J. R., M. McCoy, B. Burke, D. L. Mattey, V. Pravica, and I. V. Hutchinson, 2003: Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. J. Clin. Pathol. 56, 725-727.
21. Kerr, J. R., V. S. Cunniffe, P. Kelleher, A. J. Coats, and D. L. Mattey, 2004: Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of proinflammatory cytokines and development of B19-associated arthritis. J. Med. Virol. 74, 147-155.
22. Kerr, J. R., N. Kaushik, D. Fear, D. A. Baldwin, E. F. Nuwaysir, and I. M. Adcock, 2005a: Single-nucleotide polymorphisms associated with symptomatic infection and differential human gene expression in healthy seropositive persons each implicate the cytoskeleton, integrin signaling, and oncosuppression in the pathogenesis of human parvovirus B19 infection. J. Infect. Dis. 192, 276-289.
23. Kerr, J. R., N. B. Nixon, and D. L. Mattey, 2005b: An association between the transforming growth factor-β 1 +869*T allele and the HLA 'shared epitope' in symptomatic acute parvovirus B19 infection but not in rheumatoid arthritis (RA). Poster at International Parvovirus Meeting, Leipzig, Germany.
24. Klouda, P. T., S. A. Corbin, B. A. Bradley, B. J. Cohen, and A. D. Woolf, 1986: HLA and acute arthritis following human parvovirus infection. Tissue Antigens 28, 318-319.
25. Lunardi, C., M. Tiso, L. Borgato, L. Nanni, R. Millo, G. de Sandre, A. Bargellesi Severi, and A. C. Puccetti, 1998: Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur. J. Immunol. 28, 936-948.
26. Mattey, D. L., N. Nixon, P. T. Dawes, and J. Kerr, 2005: Assocition of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis. Ann. Rheum. Dis. 64, 1190-1194.
27. Magro, C. M., A. N. Crowson, M. Dawood, and G. J. Nuovo, 2002: Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases. J. Rheumatol. 29, 1227-1235.
28. Mikovits, J., F. Ruscetti, W. Zhu, R. Bagni, D. Dorjsuren, and R. Shoemaker, 2001: Potential cellular signatures of viral infections in human hematopoietic cells. Dis. Markers 17, 173-178.
29. Munakata, Y., T. Saito-Ito, K. Kumura-Ishii, J. Huang, T. Kodera, T. Ishii, Y. Hirabayashi, Y. Koyanagi, and T. Sasaki, 2005. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood. Aug 2; doi: 10.1182/blood-2005-03-0536.
30. Nikkari, S., T. Vuorinen, P. Kotilainen, and K. Lammintausta, 1999: Presence of parvovirus B19 DNA in the skin of healthy individuals. Arthritis Rheum. 42, S338.
31. Oldstone, M. B. 1998: Viral persistence: mechanisms and consequences. Curr. Opin. Microbiol. 1, 436-441.
32. Pallier, C., A. Greco, J. Le Junter, A. Saib, I. Vassias, and F. Morinet, 1997: The 3′ untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in non-permissive cells. J. Virol. 71, 9482-9489.
33. Reed, J. L., B. Kucukcetin, and S. Koenig, 2000: Mechanisms of parvovirus B19 persistence in peripheral blood mononuclear cells (PBMC). Infect. Dis. Rev. 2, 169.
34. Siegl, G. 1988: Patterns of parvovirus disease in animals. In: Pattison, J. R. (ed.), Parvoviruses and Human Disease, pp. 43-67. CRC Press, Boca Raton, FL.
35. Soderlund, M., R. von Essen, J. Haapasaari, U. Kiistala, O. Kiviluoto, and K. Hedman, 1997: Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 349, 1063-1065.
36. Summerford, C., and R. J. Samulski, 1998: Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445.
37. Takeda, S., C. Takaeda, E. Takazakura, and J. Haratake, 2001: Renal involvement induced by human parvovirus B19 infection. Nephron 89, 280-285.
38. Tolfvenstam, T., A. Oxenius, D. A. Price, B. L. Shacklett, H. M. Spiegel, K. Hedman, O. Norbeck, M. Levi, K. Olsen, M. Kantzanou, D. F. Nixon, K. Broliden, and P. Klenerman, 2001: Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19. J. Virol. 75, 540-543.
39. de la Torre, J. C., P. Borrow, and M. B. Oldstone, 1991: Viral persistence and disease: cytopathology in the absence of cytolysis. Br. Med. Bull. 47, 838-851.
40. Von Landenberg, P., H. W. Lehmann, A. Knoll, S. Dorsch, and S. Modrow, 2003: Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum. 48, 1939-1947.
41. Wagner, A. D., J. J. Goronzy, E. L. Matteson, and C. M. Weyand, 1995: Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin. Proc. 70, 261-265.
42. Weigel-Kelley, K. A., M. C. Yoder, and A. Srivastava, 2003: Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement for functional activation of beta1 integrin for viral entry. Blood 102, 3927-3933.
43. Wu, L., J. Chau, R. P. Young, V. Pokorny, G. D. Mills, R. Hopkins, L. McLean, and P. N. Black, 2004: Transforming growth factorbeta( 1) genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 59, 126-129.
44. Yamada, Y., A. Miyauchi, J. Goto, Y. Takagi, H. Okuizumi, M. Kanematsu, M. Hase, H. Takai, A. Harada, and K. Ikeda, 1998: Association of a polymorphism of the transforming growth factorbeta 1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res. 13, 1569-1576.
45. Yokota, M., S. Ichihara, T. L. Lin, N. Nakashima, and Y. Yamada, 2000: Association of a T29 → C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101, 2783-2787.